Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.

ABSTRACT:

Background

Myelosuppression is the major toxicity encountered during temozolomide chemoradiotherapy for newly diagnosed glioblastoma.

Methods

We assessed the association of myelosuppression (neutropenia, thrombocytopenia, anemia, and lymphopenia) during temozolomide chemoradiotherapy alone or in combination with experimental agents with progression-free survival (PFS) or overall survival (OS) in 2073 patients with newly diagnosed glioblastoma enrolled into five clinical trials: CENTRIC, CORE, EORTC 26082, AVAglio, and EORTC 26981. A landmark Cox model was used. For each primary association analysis, a significance level of 1.7% was used.

Results

Lower neutrophil counts at baseline were associated with better PFS (P = .011) and OS (P < .001), independently of steroid i

SUBMITTER: Le Rhun E 

PROVIDER: S-EPMC9435483 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature